Propafenone Shortage: What Providers and Prescribers Need to Know in 2026

Patients on propafenone (Rythmol, Rythmol SR) for atrial fibrillation, PSVT, or ventricular arrhythmias may encounter pharmacy stocking gaps that require clinical attention. This briefing provides cardiologists, electrophysiologists, and prescribing clinicians with the current availability picture, guidance on therapeutic alternatives, and practical tools to support affected patients.

Current Availability Status (2026)

As of 2026, propafenone hydrochloride is not listed on the FDA Drug Shortages database as having a national shortage. The drug is manufactured by multiple generic producers including ANI Pharmaceuticals, Strides Pharma, and Aurobindo, which provides supply redundancy. Both the immediate-release (IR) tablet formulation (150 mg, 225 mg, 300 mg) and the extended-release (ER) capsule formulation (225 mg, 325 mg, 425 mg) remain commercially available.

However, providers should be aware that localized stocking gaps occur, particularly for the ER formulation and for less common strengths. Patients may encounter delays filling prescriptions at small independent or community pharmacies, and some distributor allocation issues affect specific geographic regions. The extended-release capsules are especially prone to stocking gaps as they are dispensed in lower volume.

Clinical Risks of Propafenone Interruption

Abrupt discontinuation of propafenone carries meaningful clinical risk. As a Class IC antiarrhythmic used for rhythm control, interruptions may lead to:

• Recurrence of atrial fibrillation or PSVT with potentially symptomatic episodes
• Return of life-threatening ventricular arrhythmias in patients prescribed for that indication
• Loss of AF-related stroke prevention benefit, particularly if anticoagulation coverage is suboptimal
• Increased emergency department visits or hospitalizations for symptomatic arrhythmia recurrence

Therapeutic Alternatives: Clinical Considerations

If propafenone unavailability necessitates a therapeutic substitution, the following agents should be considered based on the patient's underlying cardiac structure, renal function, and indication:

Flecainide (Class IC) — Preferred Substitution in Structurally Normal Hearts

Flecainide is the most pharmacologically similar alternative to propafenone. Both are Class IC sodium channel blockers with comparable efficacy in AF rhythm control and PSVT suppression. Key clinical distinctions:

• Flecainide lacks propafenone's mild beta-adrenergic blocking activity and calcium channel blocking properties. Patients may require concurrent AV nodal blocking agents if rate control was partially achieved by propafenone's beta-blocking effects.
• Flecainide is dosed twice daily (100-200 mg BID), which may be simpler than propafenone's TID regimen.
• Both agents are contraindicated with coronary artery disease, structural heart disease, and depressed LVEF per the CAST trial data.

Dronedarone (Class III) — For Patients with Structural Heart Disease (Excluding Severe HF)

Dronedarone (Multaq) carries a Class IIa/Level A guideline recommendation for rhythm control in patients with paroxysmal or persistent AF in sinus rhythm with structural heart disease (excluding advanced HF or permanent AF). Unlike propafenone, dronedarone does not require in-hospital initiation in most patients. It does not have generic availability as of 2026, increasing cost burden.

Sotalol (Class II/III) — Rate/Rhythm Control with QTc Monitoring Required

Sotalol provides both beta-blocking (rate control) and Class III effects (rhythm control). Initiation requires in-hospital QTc monitoring for at least 3 doses due to TdP risk. Dosing must be renally adjusted (contraindicated with CrCl < 40 mL/min for AF indication). Approximately 37% of patients maintain sinus rhythm at one year — comparable to propafenone.

Amiodarone — Reserve for High-Risk or Refractory Cases

Amiodarone remains the most effective antiarrhythmic for AF rhythm control, with the lowest recurrence rate of any agent. However, its multi-organ toxicity profile (pulmonary, hepatic, thyroid, neurologic, dermatologic, ophthalmologic) limits its use to patients who have failed safer first-line agents or who have structural heart disease that precludes Class IC use. For short-term bridging of propafenone unavailability, amiodarone's slow loading kinetics (weeks to months to achieve steady state) make it a less practical short-term solution.

Transition Monitoring Considerations

When transitioning a patient from propafenone to an alternative antiarrhythmic, providers should consider:

• Washout period: propafenone's half-life is 2-10 hours in extensive metabolizers and up to 32 hours in poor CYP2D6 metabolizers (about 6% of Caucasians)
• ECG monitoring for QRS and QTc changes with new agent initiation
• Reassess digoxin and warfarin doses: propafenone increases both, so levels may fall after discontinuation
• Patient education on symptom recognition during the transition period

How medfinder Can Support Your Practice

Directing propafenone patients to medfinder can reduce the volume of "can't find my medication" calls to your office. medfinder calls pharmacies near your patient and texts them which pharmacies have the specific propafenone formulation and strength in stock — saving both patients and office staff significant time. This is especially valuable for cardiac patients who cannot safely skip doses.

Summary for Prescribers

Propafenone is not in a declared national shortage as of 2026, but localized stocking gaps affect some patients, particularly those on the ER formulation. Proactive patient counseling — including refilling early, using mail-order pharmacy, and knowing how to find alternatives — can prevent dangerous medication gaps. When therapeutic substitution is necessary, flecainide is the most clinically appropriate alternative for patients with structurally normal hearts, with dronedarone, sotalol, or amiodarone as second-line options based on patient-specific factors.